The Trump administration’s voluntary pricing agreement with Eli Lilly and Novo Nordisk aims to control glucagon-like peptide-1 receptor agonist costs, but implementation reveals significant structural limitations. According to analysis by STAT News, the deal permits manufacturers to maintain elevated list prices—which determine insurance reimbursement rates—while using manufacturer assistance programs to offset patient out-of-pocket expenses.
This cost-shifting mechanism creates an appearance of affordability without reducing underlying drug costs that drive system-wide expenses. The voluntary nature of the agreement lacks enforcement mechanisms necessary for sustainable price reductions. Healthcare policy experts suggest that without mandatory negotiation frameworks, pharmaceutical companies retain pricing control while federal program savings remain elusive.
The agreement’s ineffectiveness raises questions about the adequacy of voluntary industry partnerships in addressing medication affordability for Medicare and Medicaid beneficiaries.
Read the full article on GMJ Newsroom.
Was this article helpful?
